sechenovSechenov Medical JournalСеченовский вестник2218-73322658-3348Сеченовский Университетsechenov-603Research ArticleINTERNAL MEDICINEВНУТРЕННИЕ БОЛЕЗНИThe clinical significance of adiponectimics in formation of affected target-organs during the metabolic syndrome associated with nonalcoholic fatty liver diseaseКлиническое значение адипонектинемии в формировании поражения органовмишеней при метаболическом синдроме, ассоциированном с неалкогольной жировой болезнью печениСагиноваЕ. А.SaginovaE. A.

к.м.н., ассистент кафедры терапии и профболезней

PhD, assistant of the chair of therapy and occupational diseases

СевероваМ. М.SeverovaM. M.

аспирант кафедры терапии и профболезней

post-graduate student of the chair of therapy and occupational diseases

ГаллямовМ. Г.GallyamovM. G.

аспирант кафедры внутренних болезней

post-graduate student of the chair of internal medicine

ЕрмаковН. В.ErmakovN. V.

к.б.н., зав. лабораторией по разработке диагностических тест-систем

PhD, head of developing the diagnostic test systems laboratory

РодинаА. В.RodinaA. V.

к.б.н., старший научный сотрудник ГУЗ «Московский научно-исследовательский институт медицинской экологии»; ассистент кафедры биохимии Первого МГМУ им. И. М. Сеченова

PhD, senior research fellow of the Moscow research institute of medical ecology; assistant of the chair of biochemistry of the First MSMU named after I. M. Sechenov

ФоминВ. В.FominV. V.

Виктор Викторович Фомин, профессор кафедры терапии и профболезней, декан факультета довузовского образования

119435, г. Москва, ул. Россолимо, д. 11 стр. 5 (клиника профболезней) Телефон: 8 (495) 242-03-00

MD, prof. of the chair of therapy and occupational diseases, dean of the faculty of pre-university education

fomin@mmascience.ruМухинН. А.MukhinN. A.

д.м.н., академик РАМН, профессор, зав. кафедрой терапии и профболезней, директор клиники нефрологии, внутренних и профессиональных болезней им. Е. М. Тареева Университетской клинической больницы № 3

MD, corresp. member of RAMS, prof., head of the chair of therapy and occupational diseases, director of the clinic of nephrology, medical and occupational diseases named after E. M. Tareev of the university hospital № 3

Первый МГМУ им. И. М. СеченоваРоссияFirst MSMU named after I. M. SechenovRussian FederationМГУ им. М. В. ЛомоносоваРоссияMoscow state university named after M. V. LomonosovRussian FederationГУЗ «Московский научноисследовательский институт медицинской экологии»РоссияMoscow research institute of medical ecologyRussian FederationГУЗ «Московский научно-исследовательский институт медицинской экологии»; Первый МГМУ им. И. М. СеченоваРоссияMoscow research institute of medical ecology; First MSMU named after I. M. SechenovRussian Federation20113003201101-21825Copyright © Saginova E.A., Severova M.M., Gallyamov M.G., Ermakov N.V., Rodina A.V., Fomin V.V., Mukhin N.A., 20112011Сагинова Е.А., Северова М.М., Галлямов М.Г., Ермаков Н.В., Родина А.В., Фомин В.В., Мухин Н.А.Saginova E.A., Severova M.M., Gallyamov M.G., Ermakov N.V., Rodina A.V., Fomin V.V., Mukhin N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sechenovmedj.com/jour/article/view/603

The goal of this research is to estimate the clinical significance of adiponectimics in formation of affected target-organs during the metabolic syndrome associated with nonalcoholic fatty liver disease.

Цель исследования – оценка клинического значения адипонектинемии в формировании поражения органов-мишеней при метаболическом синдроме, ассоциированном с неалкогольной жировой болезнью печени.

адипонектинадипокиныинсулинорезистентностьнеалкогольная жировая болезнь печениметаболический синдромпоражение органов-мишенейабдоминальное ожирениеadiponectinmetabolic syndromenonalcoholic fatty liver diseaseinsulinoresistancetarget organ damageИсследование выполнено в рамках Гранта Президента РФ для государственной поддержки молодых российских ученых – кандидатов наук (конкурс – МК-2010), договор № 02.120.11.8327-МК от 28.06.2010. по теме «Факторы развития и прогрессирования нефропатий у больных ожирением».ReferencesRitchie S.A., Connell J.M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 2007; 17 (4): 319–326.Ritchie S.A., Connell J.M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 2007; 17 (4): 319–326.Antuna-Puente B., Feve B., Fellahi S. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008; 34 (1): 2–11.Antuna-Puente B., Feve B., Fellahi S. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008; 34 (1): 2–11.Anubhuti, Arora S. Leptin and its metabolic interactions: an update. Diabetes Obes. Metab. 2008; 10 (11): 973–993.Anubhuti, Arora S. Leptin and its metabolic interactions: an update. Diabetes Obes. Metab. 2008; 10 (11): 973–993.Han S.H., Sakuma I., Shin E.K., Koh K.K. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis. 2009; 52 (2): 126–140.Han S.H., Sakuma I., Shin E.K., Koh K.K. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis. 2009; 52 (2): 126–140.Han S.H., Quon M.J., Kim J.A., Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J. Am. Coll. Cardiol. 2007; 49 (5): 531–538.Han S.H., Quon M.J., Kim J.A., Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J. Am. Coll. Cardiol. 2007; 49 (5): 531–538.Диагностика и лечение метаболического синдрома: Российские рекомендации / Комитет экспертов ВНОК. М., 2009.Диагностика и лечение метаболического синдрома: Российские рекомендации / Комитет экспертов ВНОК. М., 2009.Диагностика и лечение артериальной гипертензии: Рекомендации Рос. мед. общ-ва по артериальной гипертонии и Всерос. науч. общ-ва кардиологов / Комитет экспертов РМОАГ/ВНОК // Системные гипертензии. 2010. № 3. С. 5–26.Диагностика и лечение артериальной гипертензии: Рекомендации Рос. мед. общ-ва по артериальной гипертонии и Всерос. науч. общ-ва кардиологов / Комитет экспертов РМОАГ/ВНОК // Системные гипертензии. 2010. № 3. С. 5–26.Huang Y., Chen Y., Xu M. et al. Low-grade albuminuria is associated with carotid intima-media thickness in Chinese type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2010; 95 (11): 5122–5128.Huang Y., Chen Y., Xu M. et al. Low-grade albuminuria is associated with carotid intima-media thickness in Chinese type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2010; 95 (11): 5122–5128.Wachtell K., Olsen M.H., Dahlöf B. et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J. Hypertens. 2002; 20 (3): 405–412.Wachtell K., Olsen M.H., Dahlöf B. et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J. Hypertens. 2002; 20 (3): 405–412.Yasui K., Sumida Y., Mori Y. et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism. 2010 Sep 1 [Epub ahead of print].Yasui K., Sumida Y., Mori Y. et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism. 2010 Sep 1 [Epub ahead of print].Chang Y., Ryu S., Sung E. et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008; 57 (4): 569–576.Chang Y., Ryu S., Sung E. et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008; 57 (4): 569–576.Targher G., Chonchol M., Bertolini L. et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J. Am. Soc. Nephrol. 2008; 19 (8): 1564–1570.Targher G., Chonchol M., Bertolini L. et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J. Am. Soc. Nephrol. 2008; 19 (8): 1564–1570.Goland S., Shimoni S., Zornitzki T. et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 2006; 40 (10): 949–955.Goland S., Shimoni S., Zornitzki T. et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 2006; 40 (10): 949–955.Salvi P., Ruffini R., Agnoletti D. et al. Increased arterial stiff-ness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J. Hypertens. 2010; 28 (8): 1699–1707.Salvi P., Ruffini R., Agnoletti D. et al. Increased arterial stiff-ness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J. Hypertens. 2010; 28 (8): 1699–1707.Kim H.C., Kim D.J., Huh K.B. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009; 204 (2): 521–525.Kim H.C., Kim D.J., Huh K.B. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009; 204 (2): 521–525.Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006; 151:175-183.Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006; 151:175-183.Мухин Н.А., Фомин В.В., Сагинова Е.А. и др. Эндотелиальная дисфункция и поражение почек при ожирении // Вестник РАМН. 2006. № 12: С. 25–31.Мухин Н.А., Фомин В.В., Сагинова Е.А. и др. Эндотелиальная дисфункция и поражение почек при ожирении // Вестник РАМН. 2006. № 12: С. 25–31.Oda N., Imamura S., Fujita T. et al. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism. 2008; 57 (2): 268–273.Oda N., Imamura S., Fujita T. et al. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism. 2008; 57 (2): 268–273.Thorand B., Zierer A., Baumert J. et al. Associations between leptin and the leptin / adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA / KORA Augsburg study 1984–2002. Diabet. Med. 2010 Sep; 27(9): 1004–1011.Thorand B., Zierer A., Baumert J. et al. Associations between leptin and the leptin / adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA / KORA Augsburg study 1984–2002. Diabet. Med. 2010 Sep; 27(9): 1004–1011.Saarikoski L.A., Huupponen R.K., Viikari JS. et al. Adiponectin is related with carotid artery intima-media thickness and brachial flow-mediated dilatation in young adults – the Cardiovascular Risk in Young Finns Study. Ann. Med. 2010; 42 (8): 603–611.Saarikoski L.A., Huupponen R.K., Viikari JS. et al. Adiponectin is related with carotid artery intima-media thickness and brachial flow-mediated dilatation in young adults – the Cardiovascular Risk in Young Finns Study. Ann. Med. 2010; 42 (8): 603–611.Huang S.S., Huang P.H., Chen Y.H. et al. Association of adiponectin with future cardiovascular events in patients after acute myocardial infarction. J. Atheroscler. Thromb. 2010; 17 (3): 295–303.Huang S.S., Huang P.H., Chen Y.H. et al. Association of adiponectin with future cardiovascular events in patients after acute myocardial infarction. J. Atheroscler. Thromb. 2010; 17 (3): 295–303.Norata G.D., Raselli S., Grigore L. et al. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke. 2007; 38(10): 2844-2846Norata G.D., Raselli S., Grigore L. et al. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke. 2007; 38(10): 2844-2846Cesari M., Pessina A.C., Zanchetta M. et al. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients. J. Intern. Med. 2006; 260(5): 474-483Cesari M., Pessina A.C., Zanchetta M. et al. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients. J. Intern. Med. 2006; 260(5): 474-483Hashimoto N., Kanda J., Nakamura T. et al. Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism. 2006; 55(12): 1653-1657Hashimoto N., Kanda J., Nakamura T. et al. Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism. 2006; 55(12): 1653-1657Uribe M., Zamora-Valdés D., Moreno-Portillo M. et al. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann. Hepatol. 2008; 7 (1): 67–71.Uribe M., Zamora-Valdés D., Moreno-Portillo M. et al. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann. Hepatol. 2008; 7 (1): 67–71.Hindle A.K., Edwards C., Mendonsa A. et al. Adiponectin but not leptin is involved in early hepatic disease in morbidly obese patients. Surg. Endosc. 2010; 24 (7): 1547– 1551.Hindle A.K., Edwards C., Mendonsa A. et al. Adiponectin but not leptin is involved in early hepatic disease in morbidly obese patients. Surg. Endosc. 2010; 24 (7): 1547– 1551.Ma H., Gomez V., Lu L. et al. Expression of adiponectin and its receptors in livers of morbidly obese patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2009; 24 (2): 233–237.Ma H., Gomez V., Lu L. et al. Expression of adiponectin and its receptors in livers of morbidly obese patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2009; 24 (2): 233–237.Jiang L.L., Li L., Hong X.F. et al. Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. Eur. J. Gastroenterol. Hepatol. 2009; 21 (6): 662–666.Jiang L.L., Li L., Hong X.F. et al. Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. Eur. J. Gastroenterol. Hepatol. 2009; 21 (6): 662–666.

The authors declare that there are no conflicts of interest present.